Zenas BioPharma Files FDA Application for Obexelimab in IgG4-RD
Zenas BioPharma files FDA application for obexelimab in IgG4-RD, showing 56% reduction in flare risk versus placebo in phase...
No videos found.
Lilly Licenses GLP-2 Analog Sonefpeglutide from Hanmi for $1.26B
Lilly licenses GLP-2 analog sonefpeglutide from Hanmi for $1.26B, betting on intestinal repair applications beyond short bowel syndrome.
NeuroThera Labs Gets Conditional Approval to Acquire CliniQuantum
NeuroThera Labs gains conditional TSX approval to acquire a majority stake in CliniQuantum, a quantum analytics firm for clinical...
Pacira Defends 5×30 Strategy as Board Faces Proxy Challenge
Pacira defends 5x30 strategy against proxy challenge, citing 31% stock gain, record revenues of $726.4M, and accelerating EXPAREL volume...
VERAXA Biotech Raises $27.5M Debt and $50M Equity Line Ahead of Nasdaq Listing
VERAXA Biotech raises $27.5M debt and $50M equity line ahead of Nasdaq listing through SPAC merger with Voyager Acquisition...
BioXcel’s IGALMI Shows Sustained Benefit in At-Home Agitation Trial
BioXcel's IGALMI demonstrates sustained benefit in at-home agitation trial, with efficacy maintained across repeated dosing over 12 weeks.
ViCentra Triples Insulin Pump Production Capacity via Phillips Medisize Deal
ViCentra triples insulin pump production capacity through Phillips Medisize partnership, enabling expansion into German and European markets.
Zenas BioPharma Seeks FDA Approval for Obexelimab in IgG4-Related Disease
Zenas BioPharma files for FDA approval for obexelimab in IgG4-related disease, showing 56% reduction in flare risk in Phase...
The Regulatory Data Gap Is Now a Competitive Moat — and Most Sponsors Are on the Wrong Side of It
Nature Reviews Drug Discovery's 2026 RWE framework signals a regulatory inflection point: sponsors who master data infrastructure will compress...
Pacira BioSciences Defends Board Against Activist Challenge Amid Record Revenue
Pacira BioSciences defends board seats against activist challenge while posting record $726.4M revenue and advancing its diversified pipeline strategy.